Guardian Pharmacy Services GRDN
- Market cap
- $2.5B
- PE
- 38.3×
- Forward PE
- n/m
- not a meaningful number
- Price to sales
- 1.7×
- EV/EBIT
- 28.7×
- Revenue, 12 months
- $1.5B
- +10% on a year ago
- Net margin
- 4.5%
- Free cash flow yield
- n/m
- not a meaningful number
Guardian Pharmacy Services trades at 38.3× trailing earnings. Revenue was $1.5B over the last twelve months, up 10% on a year earlier with a 5% net margin.
Charts
Financials
| Income statement | Q3 FY23 | Q4 FY23 | Q1 FY24 | Q2 FY24 | Q3 FY24 | Q4 FY24 | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| $262.7M | $281.1M | $275.4M | $300M | $314.4M+20% | $338.6M+21% | $329.3M+20% | $344.3M+15% | $377.4M+20% | $397.6M+17% | $336.6M+2% | $351.8M+2% | |
| Cost of revenue | $210.5M | $226.5M | $220.3M | $238.7M | $253.5M+20% | $271.5M+20% | $265M+20% | $276.2M+16% | $302.7M+19% | $312.1M+15% | $260.3M−2% | $271.7M−2% |
| Gross profit | $52.2M | $54.6M | $55.1M | $61.3M | $60.9M+17% | $67.1M+23% | $64.3M+17% | $68.1M+11% | $74.7M+23% | $85.5M+27% | $76.3M+19% | $80M+18% |
| SG&A | $58.5M | $39.1M | $47.2M | $44.3M | $165.5M+183% | $50.3M+29% | $51.3M+9% | $55.6M+26% | $58.4M−65% | $54.7M+9% | $58.6M+14% | $59.4M+7% |
| −$6.3M | $15.5M | $7.9M | $17M | −$104.6M+1553% | $16.8M+8% | $13M+64% | $12.6M−26% | $16.4M | $30.8M+84% | $17.7M+36% | $20.6M+64% | |
| Interest expense | $716K | $739K | $765K | $1.1M | $1M+43% | $421K−43% | $170K−78% | $172K−84% | $160K−84% | $163K−61% | $154K−9% | $154K−11% |
| Pre-tax income | −$7M | $14.6M | $7.1M | $15.8M | −$105.6M+1410% | $16.2M+11% | $13.1M+85% | $12.6M−21% | $16.6M | $31.1M+92% | $18.3M+40% | $29.8M+137% |
| n/a | n/a | $0 | $0 | $176K | $4.4M | $3.8M | $3.8M | $7M+3899% | $9.8M+125% | $4.7M+24% | $7.7M+104% | |
| Net income | n/a | n/a | $0 | $0 | −$122M | $11.9M | $9.4M | $9M | $9.8M | $20.9M+75% | $13.3M+41% | $21.9M+142% |
| n/a | n/a | n/a | n/a | −$2.00 | $0.18 | $0.15 | $0.14 | $0.15 | $0.33+83% | $0.21+40% | $0.34+143% | |
| n/a | n/a | n/a | n/a | 61.1M | 64.6M | 62.9M | 63.2M | 63.4M+4% | 63.6M−1% | 63.7M+1% | 63.8M+1% |
Net income: Q1 FY24: 6 months less the 3 months printed beside them.
EPS, diluted: Q4 FY24 and Q4 FY25: quarter's net income to common over its shares, to the cent.
Diluted shares: Q4 FY24 and Q4 FY25: share-days: the 12-month average less the 9-month, weighted by days.
From each company's 10-Q and 10-K filings, the newest version of each figure. Quarters are as filed (a fourth quarter is the year less its first nine months), fiscal years as the 10-K prints them, restated where a later 10-K restated them, and balance sheet lines as of the period's end. A quarter whose 10-Q isn't filed yet is from the company's results release. Growth is on the same period a year earlier. A dash is a period with no figure for the line: the filing doesn't print it, or it hasn't been read yet.
Peers
Companies in Healthcare nearest Guardian Pharmacy Services' size, closest first.
| Company | Market cap | PE | Its 10y median PE | Fwd PE | P/S | Revenue growth | Net margin |
|---|---|---|---|---|---|---|---|
| GRDNGuardian Pharmacy Services | $2.5B | 38.3× | 47.8× | 1.7× | +10% | 4.5% | |
| TMDXTransMedics | $2.5B | 18.4× | 56.8× | 3.7× | +26% | 22.7% | |
| ADMAAdma Biologics | $2.4B | 15.3× | 21.5× | 4.7× | +8% | 33.0% | |
| MDPediatrix Medical | $2.4B | 14.0× | 13.4× | 1.2× | +1% | 9.0% | |
| UFPTUFP Technologies | $2.3B | 31.9× | 25.6× | 3.6× | +7% | 11.4% | |
| ADUSAddus HomeCare | $2.3B | 21.4× | 32.4× | 1.5× | +16% | 7.1% | |
| PBHPrestige Consumer Healthcare | $2.3B | 13.4× | 15.3× | 2.0× | −1% | 15.6% | |
| NRIXNurix Therapeutics | $2.8B | 11.0× | 10.8× | 3.9× | n/m | 42.0% | |
| PGNYProgyny | $2.2B | 31.5× | 55.1× | 1.7× | +6% | 6.0% | |
| PRVAPrivia Health | $2.9B | 107× | 158× | 1.2× | +24% | 1.2% | |
| VCELVericel | $2.2B | 92.5× | 158× | 7.1× | +23% | 7.9% | |
| Peer median | $2.3B | 19.9× | 29.0× | 2.8× | +8% | 10.2% |
More on Guardian Pharmacy Services
Each number over time
Its groups
About
- Industry
- Medical - Pharmaceuticals
- Sector
- Healthcare
Valuation data, not investment advice. Prices as of .